Oncogenesis driven by the Ras/Raf pathway requires the SUMO E2 ligase Ubc9

The small GTPase KRAS is frequently mutated in human cancer and currently there are no targeted therapies for KRAS mutant tumors. Here, we show that the small ubiquitin-like modifier (SUMO) pathway is required for KRAS-driven transformation. RNAi depletion of the SUMO E2 ligase Ubc9 suppresses 3D gr...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Proc Natl Acad Sci U S A
Autori principali: Yu, Bing, Swatkoski, Stephen, Holly, Alesia, Lee, Liam C., Giroux, Valentin, Lee, Chih-Shia, Hsu, Dennis, Smith, Jordan L., Yuen, Garmen, Yue, Junqiu, Ann, David K., Simpson, R. Mark, Creighton, Chad J., Figg, William D., Gucek, Marjan, Luo, Ji
Natura: Artigo
Lingua:Inglês
Pubblicazione: National Academy of Sciences 2015
Soggetti:
PNAS Plus
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394293/
https://ncbi.nlm.nih.gov/pubmed/25805818
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1415569112
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi